<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169427</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-91067-122</org_study_id>
    <nct_id>NCT02169427</nct_id>
  </id_info>
  <brief_title>An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites</brief_title>
  <official_title>An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the rate and routes of excretion of OPC and the
      mass balance in urine, faeces and expired air.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a single-centre, open-label ADME study in 6 healthy male subjects. Subjects received
      a single dose of 100 mg OPC, containing 3.39 MBq of [14C] OPC as oral capsules.

      The study consisted of an eligibility screening period within 3 weeks prior to drug
      administration, admission on Day -1, a treatment period involving drug administration on Day
      1 followed by matrix collections for PK purposes and safety evaluations up to Day 11,
      discharge on Day 11, six 24-hour hospitalizations on Days 14/15, 21/22 (+/ 1 day), 28/29 (+/-
      1 day), 42/43 (+/- 2 days), 56/57 (+/- 2 days) and 77/78 (+/ 3 days) for PK sample
      collections, and a follow up visit performed at least 14 days after discharge from the last
      24-hour hospitalization or at early discontinuation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Recovery of [14C]-Radioactivity</measure>
    <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
    <description>AEurine: Cumulative Recovery of [14C]-Radioactivity in urine AEfaeces: Cumulative Recovery of [14C]-Radioactivity in urine AEair: Cumulative Recovery of [14C]-Radioactivity in urine AEtotal: Cumulative Recovery of [14C]-Radioactivity in urine
Recovery % of dose has been derived from area under the excretion rate (to infinity) from 240h onwards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Maximum Concentration</measure>
    <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
    <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax - Time to Attain Maximum Concentration</measure>
    <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
    <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Parkinson's Disease (PD)</condition>
  <arm_group>
    <arm_group_label>Opicapone (OPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg OPC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC</intervention_name>
    <description>The drug substance of 100 mg OPC was administered as 1 capsule.</description>
    <arm_group_label>Opicapone (OPC)</arm_group_label>
    <other_name>BIA 9-1067</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gender: male

          2. Age: 18 - 55 years, inclusive

          3. Body Mass Index (BMI): 18.0 - 30.0 kg/m2, inclusive Body weight (kg)and height2 (m2)

          4. Ability and willingness to abstain from alcohol, methylxanthine-containing beverages
             or food (coffee, tea, cola, chocolate, &quot;powerdrinks&quot;) and grapefruit (juice) from 48
             hours prior to entry in the clinical research centre until discharge

          5. Medical history without major pathology

          6. Resting supine blood pressure and a resting pulse rate showing no clinically relevant
             deviations as judged by the MI

          7. Computerised (12-lead) electrocardiogram (ECG) recording without signs of clinically
             relevant pathology or showing no clinically relevant deviations as judged by the MI

          8. Willingness to use adequate contraception from the time of dosing until 3 months after
             the follow-up visit

          9. All values for haematology and for clinical chemistry tests of blood and urine within
             the normal range or showing no clinically relevant deviations as judged by the MI

         10. Willingness to sign the written ICF

        Exclusion Criteria:

          1. Evidence of clinically relevant pathology

          2. Mental handicap

          3. History of relevant drug and/or food allergies

          4. Regular/routine treatment with non-topical medications within 30 days prior to
             entrance into the clinical research centre

          5. Smoking (less than 60 days prior to drug administration)

          6. History of alcohol abuse or drug addiction (including soft drugs like cannabis
             products)

          7. Use of concomitant medication, except for acetaminophen (paracetamol), which was
             allowed up to 3 days before entrance into the clinical research centre. Multivitamins
             and vitamin C were allowed up to 7 days before entrance into the clinical research
             centre. All other medication (including over the counter medication, health
             supplements, and herbal remedies such as St. John's wort extract) was to be stopped at
             least 14 days prior to entrance into the clinical research centre

          8. Participation in a drug study within 60 days prior to drug administration.
             Participation in more than 3 other drug studies in the 10 months preceding
             administration of study drug

          9. Donation of more than 50 mL of blood within 60 days prior to drug administration.
             Donation of more than 1.5 litres of blood in the 10 months preceding administration of
             study drug

         10. Participation in another ADME study with a radiation burden -0.1 mSv in the period of
             1 year before the start of the study

         11. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X rays of
             thorax and bony skeleton - excluding spinal column), during work or during
             participation in a medical study in the previous year

         12. Irregular defecation pattern (less than once per 2 days)

         13. Positive screen on drugs of abuse (opiates, methadone, cocaine, amphetamines,
             cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol)

         14. Intake of more than 24 units of alcohol per week (1 unit of alcohol equals
             approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)

         15. Positive screen on hepatitis B surface antigen (HBsAg)

         16. Positive screen on anti-hepatitis C virus (HCV)

         17. Positive screen on anti- human immunodeficiency virus (HIV) 1/2

         18. Illness within 5 days prior to drug administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <results_first_submitted>July 22, 2015</results_first_submitted>
  <results_first_submitted_qc>July 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2015</results_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease (PD)</keyword>
  <keyword>BIA 9-1067</keyword>
  <keyword>Opicapone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opicapone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Opicapone (OPC)</title>
          <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Opicapone (OPC)</title>
          <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cumulative Recovery of [14C]-Radioactivity</title>
        <description>AEurine: Cumulative Recovery of [14C]-Radioactivity in urine AEfaeces: Cumulative Recovery of [14C]-Radioactivity in urine AEair: Cumulative Recovery of [14C]-Radioactivity in urine AEtotal: Cumulative Recovery of [14C]-Radioactivity in urine
Recovery % of dose has been derived from area under the excretion rate (to infinity) from 240h onwards</description>
        <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opicapone (OPC)</title>
            <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Recovery of [14C]-Radioactivity</title>
          <description>AEurine: Cumulative Recovery of [14C]-Radioactivity in urine AEfaeces: Cumulative Recovery of [14C]-Radioactivity in urine AEair: Cumulative Recovery of [14C]-Radioactivity in urine AEtotal: Cumulative Recovery of [14C]-Radioactivity in urine
Recovery % of dose has been derived from area under the excretion rate (to infinity) from 240h onwards</description>
          <units>Recovery % of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEurine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEfaeces</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEtotal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Maximum Concentration</title>
        <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
        <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opicapone (OPC)</title>
            <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Concentration</title>
          <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
          <units>ng [eq]/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>14C plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7302" spread="3918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14C blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1920" spread="813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPC plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="757" spread="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIA 9-1103 plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" spread="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax - Time to Attain Maximum Concentration</title>
        <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
        <time_frame>pre-dose and 0-6, 6-12, 12-24, 24-48, 48 72, 72-96, 96 120, 120-144, 144-168, 168-192, 192-216 and 216-240 hours post-dose; 24-hour collections on Days 14/15, 21/22, 28/29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Opicapone (OPC)</title>
            <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax - Time to Attain Maximum Concentration</title>
          <description>BIA 9-1103 is a Opicapone (OPC, BIA 9-1067) metabolite</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>14C plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14C blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPC plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BIA 9-1103 plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Opicapone (OPC)</title>
          <description>100 mg OPC
OPC: The drug substance of 100 mg OPC was administered as 1 capsule.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Frequent Bowel Movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

